# Intracellular Calcium Dysregulation: The Hidden Culprit in the Diabetes–Gout Nexus

## TL;DR

Intracellular calcium imbalance may be a key factor linking type 2 diabetes and gout, affecting insulin secretion and inflammation.

## Contribution

This paper proposes intracellular calcium dysregulation as a central pathological amplifier linking type 2 diabetes and gout.

## Key findings

- Calcium signaling disturbances impair pancreatic β-cell function and promote insulin resistance.
- Calcium overload disrupts uric acid excretion and activates inflammatory pathways.
- Targeted calcium signaling interventions may offer new therapeutic strategies for managing diabetes and gout.

## Abstract

Type 2 diabetes and gout are both common metabolic disorders that frequently occur together. Research indicates that disturbances in intracellular calcium balance may be a key molecular factor linking the development of these two diseases. Calcium signaling disturbances promote the synergistic progression of both diseases through multiple pathways: In pancreatic β-cells, endoplasmic reticulum (ER) calcium imbalance triggers ER stress, mitochondrial dysfunction, and apoptosis, autophagy, and pyroptosis, leading to impaired insulin secretion. Concurrently, calcium overload exacerbates insulin resistance by disrupting insulin signal transduction in peripheral tissues, while hyperinsulinemia further inhibits uric acid excretion through activation of the renal URAT1 transporter, creating a vicious cycle. Additionally, calcium homeostasis dysregulation activates the NLRP3 inflammasome and promotes the release of pro-inflammatory cytokines, aggravating chronic low-grade inflammation, which further deteriorates β-cell function and peripheral metabolic disorders, collectively driving the pathological link between type 2 diabetes and gout. Although calcium channel modulators show potential in improving β-cell function and reducing inflammation, their clinical application faces challenges such as tissue-specific effects and a lack of high-quality clinical trials. We propose that intracellular calcium dysregulation serves as a central pathological amplifier in the diabetes–gout nexus. Future research on targeted calcium signaling interventions, guided by this integrative concept, may help overcome the therapeutic challenges in managing type 2 diabetes complicated by gout.